Bavarian Nordic inks license and supply deal with Nuance Pharma

21 March 2022

Shares of Denmark-based Bavarian Nordic (OMX: BAVA) were up 4% at 175.05 Danish kroner this morning, as is said it has entered into an exclusive license and supply agreement with Nuance Pharma, a Chinese specialty pharmaceutical company, on the development and commercialization of vaccine candidate MVA-BN RSV against respiratory syncytial virus (RSV) in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries1.

The agreement entails clinical development, including a Phase III trial to support regulatory approval of MVA-BN RSV in China, which will be conducted separately from the company’s own Phase III trial planned for initiation later in the first half of 2022 to support a US Biologics License Application (BLA).

Financial terms of the collaboration

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK